Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
Giuseppe Giaccone(Cornell University), David H. Johnson(Boston Children's Hospital), Michael Wolf(University of Vienna), Joachim von Pawel(Asklepios Fachkliniken München-Gauting), A Płużańska(Fundación Instituto Valenciano de Oncología), Rafael Rosell(Hospital Universitario Dexeus), Abderrahim Fandi(Heidelberg University), Joan H. Schiller(Virginia Department of Health), John Grous(Heidelberg University), U. Gatzemeier(Ontario Institute for Cancer Research), Giorgio V. Scagliotti(Ospedale San Luigi Gonzaga), Pamela Rennie(Heidelberg University), Ronald B. Natale(Cedars-Sinai Medical Center), Judith Ochs(Heidelberg University), Vincent A. Miller(Universidad San Carlos), Steven D. Averbuch(Heidelberg University), Christian Manegold(Ontario Institute for Cancer Research), Roy S. Herbst(Smilow Cancer Hospital)
Cited by 1,720
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k
Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer
|New England Journal of Medicine|2003|2.6k